These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38112449)

  • 61. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
    Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
    Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas.
    Zhang G; Tai P; Fang J; Chen A; Chen X; Cao K
    Front Oncol; 2023; 13():1157115. PubMed ID: 37051542
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pan-cancer analysis of GALNTs expression identifies a prognostic of GALNTs feature in low grade glioma.
    Mao C; Zhuang SM; Xia Z; Xiao ZW; Huang CX; Su Q; Chen J; Liao J
    J Leukoc Biol; 2022 Oct; 112(4):887-899. PubMed ID: 35075694
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 65. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
    Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
    Front Genet; 2022; 13():872186. PubMed ID: 35937991
    [No Abstract]   [Full Text] [Related]  

  • 66. CCR5 as a Prognostic Factor in Lower-Grade Glioma is Involved in the Remodeling of the Tumor Microenvironment.
    Wang F; Tao Z; Tian Z; Jin J; Dong J; Dai Y; Yu W; Tang B; Hu S
    Front Genet; 2022; 13():874896. PubMed ID: 35865011
    [No Abstract]   [Full Text] [Related]  

  • 67. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Malignant Tumor Purity Reveals the Driven and Prognostic Role of
    Lu X; Li C; Xu W; Wu Y; Wang J; Chen S; Zhang H; Huang H; Huang H; Liu W
    Front Oncol; 2021; 11():676124. PubMed ID: 34557404
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas.
    Wang M; Jia J; Cui Y; Peng Y; Jiang Y
    Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827528
    [No Abstract]   [Full Text] [Related]  

  • 70. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.
    Wang D; Sun H; Li X; Wang G; Yan G; Ren H; Hou B
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34908101
    [TBL] [Abstract][Full Text] [Related]  

  • 72. PPP1R81 correlates with the survival and cell proliferation in lower-grade glioma.
    Xiao F; Jie X; Zhou X; Guo Y; Sun GF; Lin L; Hu GW; Huang K; Guo H
    Biosci Rep; 2023 May; 43(5):. PubMed ID: 37083601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
    Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
    Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Integrated analysis of necroptosis related gene signature to predict clinical outcomes, immune status and drug sensitivity in lower grade Glioma.
    Hu X; Ma Y; Xia Y; Liu B
    Heliyon; 2024 Jan; 10(1):e23947. PubMed ID: 38192784
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma.
    Zhu J; Lin Q; Zheng H; Rao Y; Ji T
    Front Oncol; 2022; 12():897042. PubMed ID: 36505882
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of heterogeneous subtypes and a prognostic model for gliomas based on mitochondrial dysfunction and oxidative stress-related genes.
    Li J; Wang S; Chi X; He Q; Tao C; Ding Y; Wang J; Zhao J; Wang W
    Front Immunol; 2023; 14():1183475. PubMed ID: 37334354
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
    Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
    J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Optimized risk stratification strategy for glioma patients based on the feature genes of poor immune cell infiltration patterns.
    Wan HT; Su ZJ; Guo ZS; Wen P; Hong XY
    J Cancer Res Clin Oncol; 2023 Nov; 149(15):13855-13874. PubMed ID: 37535161
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance.
    Ma J; Jin Y; Gong B; Li L; Zhao Q
    Discov Oncol; 2022 Mar; 13(1):17. PubMed ID: 35312867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.